Moventig (Naloxegol)

Naloxegol, the active ingredient in Moventig, is a peripheral opioid antagonist presented as an oral tablet for oral use. It selectively blocks μ‑opioid receptors in the gastrointestinal tract, helping to restore normal bowel motility in patients who develop constipation as a side effect of opioid analgesics.

GNH USA supplies Moventig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this EU‑approved medication for healthcare providers. The company adheres to stringent quality standards and offers comprehensive logistics support for global distribution.

Moventig (naloxegol) is used to manage opioid‑induced constipation, a condition caused by reduced gastrointestinal motility during opioid therapy.

Opioid‑induced constipation: Improves bowel movements and reduces stool retention in patients receiving opioid analgesics.

Naloxegol may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Abdominal pain - Diarrhea - Nausea - Flatulence - Headache - Vomiting

Serious or Rare Side Effects: - Intestinal obstruction - Severe abdominal pain - Allergic reactions such as rash or angioedema - Pancreatitis - Severe dehydration - Elevated liver enzymes

Before prescribing Moventig, clinicians should evaluate patient-specific factors and monitor for potential complications. - Assess bowel function before initiating therapy: confirm that constipation is opioid‑related and not due to other causes. - Avoid use in patients with known or suspected mechanical gastrointestinal obstruction: naloxegol can exacerbate blockage. - Monitor for signs of dehydration or electrolyte imbalance: adjust fluid intake as needed. - Use caution in patients with hepatic impairment: dose adjustment may be required. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Naloxegol interacts with several drug classes that affect its metabolism or transport.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): may increase naloxegol exposure and risk of toxicity. - Concomitant use with other peripheral opioid antagonists: can lead to additive adverse gastrointestinal effects.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may require dose adjustment. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy of naloxegol. - P‑gp inhibitors (e.g., verapamil, amiodarone): can increase systemic concentrations of naloxegol.